Zejula® (niraparib) ZEJULA is a once-daily oral PARP inhibitor available for the maintenance treatment of women with recurrent ovarian cancer, regardless of BRCA mutation status.

Once-daily oral maintenance treatment for patients with recurrent ovarian cancer1

Watch Video Stay Connected For Patients

ZEJULA is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

Please see Important Safety Information below and full Prescribing Information.

See the pivotal trial data

Results from the phase 3 pivotal trial were published in the December 2016 issue of

The New England Journal of Medicine:

"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer."

Subscription required to view full article.

View Abstract

HEALTHCARE PROFESSIONALS ONLY

Get updates

Sign up to receive the latest news about ZEJULA.

* Required field

By clicking submit, you agree to TESARO’s Terms of Use and Privacy Policy and to receive product and disease-state information from TESARO, its affiliates, service providers, and co-promotion partners.